Annual Statements Open main menu

BRUKER CORP - Quarter Report: 2007 September (Form 10-Q)

 

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 10-Q

 

 

 

(Mark One)

 

 

x

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

 

 

 

 

 

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2007

 

 

 

 

 

 

 

o

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

 

 

 

 

 

FOR THE TRANSITION PERIOD FROM                      TO

 

Commission File Number  000-30833

 

Bruker BioSciences Corporation

(Exact name of registrant as specified in its charter)

 

DELAWARE

 

04-3110160

(State or other jurisdiction of

 

(I.R.S. Employer

incorporation or organization)

 

Identification Number)

 

40 Manning Park

Billerica, MA  01821

(Address of principal executive offices)

 

(978) 663-3660

(Registrant’s telephone number, including area code)

 

Indicate by checkmark whether the registrant:  (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  x   No  o

 

Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act).  Large accelerated filer        o  Accelerated filer        x  Non-accelerated filer o

 

Indicate by checkmark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2).  Yes  o  No x

 

As of November 5, 2007, there were 105,490,604 shares of the Registrant’s common stock outstanding.

 

 



 

Bruker BioSciences Corporation

Form 10-Q

For the Quarter Ended September 30, 2007

Index

 

 

 

 

 

 

 

 

 

 

 

PART I

 

FINANCIAL INFORMATION

 

3

ITEM 1:

 

Financial Statements:

 

3

 

 

Unaudited Condensed Consolidated Balance Sheets as of September 30, 2007 and December 31, 2006

 

3

 

 

Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2007 and 2006

 

4

 

 

Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2007 and 2006

 

5

 

 

Notes to Unaudited Condensed Consolidated Financial Statements

 

6

ITEM 2:

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

14

ITEM 3:

 

Quantitative and Qualitative Disclosures about Market Risk

 

26

ITEM 4:

 

Controls and Procedures

 

27

PART II

 

OTHER INFORMATION

 

28

ITEM 1:

 

Legal Proceedings

 

28

ITEM 1A:

 

Risk Factors

 

28

ITEM 2:

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

28

ITEM 3:

 

Defaults Upon Senior Securities

 

28

ITEM 4:

 

Submission of Matters to a Vote of Security Holders

 

28

ITEM 5:

 

Other Information

 

28

ITEM 6:

 

Exhibits

 

28

 

 

SIGNATURES

 

29

 

2



 

PART I   FINANCIAL INFORMATION

ITEM 1:  Financial Statements

 

Bruker BioSciences Corporation

Unaudited Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

 

 

 

September 30,
2007

 

December 31,
2006

 

ASSETS

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

38,904

 

$

52,147

 

Accounts receivable, net

 

85,840

 

79,604

 

Due from affiliated companies

 

6,366

 

9,028

 

Inventories

 

184,248

 

134,504

 

Other current assets

 

28,082

 

19,461

 

Total current assets

 

343,440

 

294,744

 

Property, plant and equipment, net

 

101,015

 

90,349

 

Goodwill, intangible and other assets

 

53,909

 

48,094

 

Total assets

 

$

498,364

 

$

433,187

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Short-term borrowings

 

$

21,014

 

$

21,857

 

Accounts payable

 

31,102

 

23,102

 

Due to affiliated companies

 

7,526

 

5,901

 

Customer advances

 

44,345

 

49,461

 

Deferred revenue

 

21,790

 

16,661

 

Other current liabilities

 

84,672

 

78,146

 

Total current liabilities

 

210,449

 

195,128

 

 

 

 

 

 

 

Long-term debt

 

18,078

 

22,863

 

Other long-term liabilities

 

31,321

 

23,730

 

Commitments and contingencies (Note 14)

 

 

 

 

 

Preferred stock, $0.01 par value, 5,000,000 shares authorized, none issued or outstanding at September 30, 2007 or December 31, 2006

 

 

 

Common stock, $0.01 par value, 200,000,000 shares authorized, 105,485,207 shares issued and 105,474,931 shares outstanding at September 30, 2007 and 102,561,129 shares issued and outstanding at December 31, 2006

 

1,047

 

1,020

 

Treasury stock, at cost, 10,276 shares and 0 shares at September 30, 2007 and December 31, 2006, respectively

 

(92

)

 

Other stockholders’ equity

 

237,561

 

190,446

 

Total shareholders’ equity

 

238,516

 

191,466

 

Total liabilities and shareholders’ equity

 

$

498,364

 

$

433,187

 

 

See the accompanying notes to financial statements.

 

3



 

Bruker BioSciences Corporation

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except per share data)

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

 

September 30,

 

September 30,

 

 

 

2007

 

2006

 

2007

 

2006

 

Product revenue

 

$

115,235

 

$

91,928

 

$

317,243

 

$

264,104

 

Service revenue

 

16,217

 

12,684

 

46,169

 

34,970

 

Other revenue

 

191

 

258

 

421

 

1,135

 

Total revenue

 

131,643

 

104,870

 

363,833

 

300,209

 

 

 

 

 

 

 

 

 

 

 

Cost of product revenue

 

59,924

 

50,659

 

166,525

 

143,414

 

Cost of service revenue

 

9,886

 

8,028

 

29,816

 

20,633

 

Total cost of revenue

 

69,810

 

58,687

 

196,341

 

164,047

 

Gross profit

 

61,833

 

46,183

 

167,492

 

136,162

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Sales and marketing

 

27,057

 

19,063

 

74,909

 

58,795

 

General and administrative

 

8,556

 

7,239

 

24,036

 

20,319

 

Research and development

 

14,763

 

11,936

 

42,302

 

36,495

 

Acquisition related charges

 

 

961

 

 

5,829

 

Total operating expenses

 

50,376

 

39,199

 

141,247

 

121,438

 

Operating income

 

11,457

 

6,984

 

26,245

 

14,724

 

 

 

 

 

 

 

 

 

 

 

Interest and other income (expense), net

 

(619

)

(491

)

(825

)

3,522

 

 

 

 

 

 

 

 

 

 

 

Income before income tax provision and minority interest in consolidated subsidiaries

 

10,838

 

6,493

 

25,420

 

18,246

 

 

 

 

 

 

 

 

 

 

 

Income tax provision

 

2,065

 

3,535

 

7,655

 

9,398

 

 

 

 

 

 

 

 

 

 

 

Income before minority interest in consolidated subsidiaries

 

8,773

 

2,958

 

17,765

 

8,848

 

Minority interest in consolidated subsidiaries

 

109

 

(18

)

255

 

75

 

Net income

 

$

8,664

 

$

2,976

 

$

17,510

 

$

8,773

 

 

 

 

 

 

 

 

 

 

 

Net income per common share - basic

 

$

0.08

 

$

0.03

 

$

0.17

 

$

0.09

 

Net income per common share - diluted

 

$

0.08

 

$

0.03

 

$

0.16

 

$

0.09

 

Weighted average common shares outstanding:

 

 

 

 

 

 

 

 

 

Basic

 

104,377

 

102,038

 

103,806

 

101,635

 

Diluted

 

106,679

 

102,704

 

106,484

 

102,090

 

 

See the accompanying notes to financial statements.

 

4



 

Bruker BioSciences Corporation

Unaudited Condensed Consolidated Statements of Cash Flows

(in thousands)

 

 

 

Nine Months Ended

 

 

 

September 30,

 

 

 

2007

 

2006

 

Operating activities:

 

 

 

 

 

Net cash (used in) provided by operating activities

 

$

(10,153

)

$

17,835

 

 

 

 

 

 

 

Investing activities:

 

 

 

 

 

Purchases of property and equipment

 

(13,352

)

(5,037

)

Redemption of short-term investments

 

 

46,460

 

Acquisitions, net of cash acquired

 

(2,855

)

(27,642

)

Changes in restricted cash

 

(283

)

(76

)

Net cash (used in) provided by investing activities

 

(16,490

)

13,705

 

 

 

 

 

 

 

Financing activities:

 

 

 

 

 

(Repayments of) proceeds from short-term borrowings, net

 

(6,416

)

19,521

 

(Repayments of) proceeds from long-term debt, net

 

(1,470

)

899

 

Proceeds from issuance of common stock

 

18,864

 

418

 

Repurchase of common stock

 

(92

)

 

Cash payments to shareholders

 

 

(74,021

)

Net cash provided by (used in) financing activities

 

10,886

 

(53,183

)

Effect of exchange rate changes on cash

 

2,514

 

3,162

 

Net change in cash and cash equivalents

 

(13,243

)

(18,481

)

Cash and cash equivalents at beginning of period

 

52,147

 

62,632

 

Cash and cash equivalents at end of period

 

$

38,904

 

$

44,151

 

 

 

 

 

 

 

Non-Cash Financing Activities

 

 

 

 

 

Issuance of common stock related to acquisitions

 

$

269

 

$

58,463

 

 

See the accompanying notes to financial statements.

 

5



 

Bruker BioSciences Corporation

Notes to Unaudited Condensed Consolidated Financial Statements

 

1.  Description of Business and Basis of Presentation

 

Bruker BioSciences Corporation and its wholly-owned subsidiaries (the “Company”, “we,” “us,” or “our”) design, manufacture, service and market proprietary life science and materials research systems based on mass spectrometry core technology platforms, X-ray technologies, optical emission spectroscopy (OES) technology, and infrared and Raman molecular spectroscopy technology. The Company also sells a broad range of field analytical systems for chemical, biological, radiological and nuclear (CBRN) detection. The Company maintains major technical and manufacturing centers in Europe, North America and Japan and sales offices throughout the world. The Company’s diverse customer base includes pharmaceutical, biotechnology and proteomics companies, academic institutions, advanced materials and semiconductor industries and government agencies.

 

The financial statements represent the consolidated accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated financial statements as of and for the three and nine months ended September 30, 2007 and 2006 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with Article 10 of Regulation S-X. Accordingly, the financial information presented herein does not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. The results for interim periods are not necessarily indicative of the results to be expected for the full year.

 

On July 1, 2006, the Company completed its acquisition of Bruker Optics Inc. (“Bruker Optics”). Both the Company and Bruker Optics were majority owned by five affiliated stockholders prior to the acquisition. As a result, the acquisition of Bruker Optics by the Company was considered a business combination of companies under common control. The consolidated balance sheets, statements of operations, statements of cash flows and notes to the financial statements presented in this Quarterly Report on Form 10-Q have been restated by combining the historical consolidated financial statements of the Company with those of Bruker Optics for periods prior to the acquisition.

 

The Company reports financial results on the basis of the following three business segments:

 

1.                     Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology tools for advanced X-ray and spark-OES instrumentation used in non-destructive molecular materials and elemental analysis in academic, research and industrial applications.

 

2.                     Bruker Daltonics is a leading developer and provider of life science tools based on mass spectrometry and also develops and provides a broad range of field analytical systems for CBRN detection.

 

3.                     Bruker Optics is a leading developer and provider of research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

 

2.  Public Offering of Common Stock

 

On February 12, 2007, the Company and a group of selling stockholders completed a public offering of 11,960,000 shares of its common stock, of which 2,530,000 were sold by the Company and 9,430,000 were sold by four selling shareholders, at $7.10 per share, generating net proceeds of approximately $16.9 million to the Company and approximately $63.2 million to the selling stockholders, in the aggregate.

 

3.  Acquisitions

 

On July 1, 2006, the Company completed the acquisition of all of the outstanding stock of Bruker Optics in accordance with the terms of the stock purchase agreement dated as of April 17, 2006. The acquisition of Bruker Optics represented a business combination of companies under common control due to the majority ownership of both companies by five related individuals as an affiliated shareholder group. As a result, the acquisition, as it related to the shares owned by these affiliated shareholders (approximately 96%), was accounted for at historical carrying value. The acquisition of the shares of the non-affiliated shareholders (approximately 4%) was accounted for at fair value, in a manner similar to the acquisition of a minority interest. The excess purchase price of the interest not under common control over the fair value of the related net assets was recorded as intangible assets and goodwill.

 

Upon completion of the acquisition, the Company paid an aggregate of $135 million of consideration to the Bruker Optics stockholders and holders of Bruker Optics stock options, of which approximately $79 million was paid in cash and approximately $56 million was paid in restricted unregistered shares of Company common stock. The fair value of the consideration paid for the acquisition of the minority interest was approximately $5.2 million, including cash of $4.8 million and common stock valued at

 

6



 

 $0.4 million. The value of the shares of common stock issued to the non-affiliated shareholder in connection with the merger was determined using a trailing average of the closing market prices of the Company’s stock for a period of ten consecutive trading days ending three days prior to the closing of the acquisition, which occurred on July 1, 2006.

 

The Company engaged RSM McGladrey, Inc., a third party valuation firm, to assist management in appraising the fair value of certain assets acquired.  The appraisal was completed in the second quarter of 2007. The following table summarizes the fair values of assets acquired and liabilities assumed at the date of acquisition of the minority interest (in thousands):

 

Current assets

 

$

42,387

 

Property, plant and equipment

 

13,174

 

Intangible assets

 

53,846

 

Other assets

 

72

 

Total assets

 

109,479

 

Current liabilities

 

34,488

 

Long-term debt

 

3,463

 

Other liabilities

 

2,074

 

Total liabilities assumed

 

40,025

 

Net assets

 

69,454

 

Minority interest percentage

 

4.1

%

Net assets acquired

 

2,848

 

Goodwill

 

2,294

 

Total purchase price

 

$

5,142

 

 

The purchase price for the 4.1% minority interest acquired was allocated to the net assets acquired on a pro rata basis in accordance with Statement of Financial Accounting Standards (“SFAS”) No. 141, Business Combinations. Accordingly, acquisition related intangibles total $2.2 million and are being amortized over four years. In addition, approximately $2.7 million of acquired intangible assets were assigned to in-process research and development projects of which the 4.1% minority interest, or approximately $0.1 million, was written off at the date of acquisition in accordance with FASB Interpretation No. 4, Applicability of FASB Statement No. 2 to Business Combinations Accounted for by the Purchase Method. The projects that were estimated to qualify as acquired in-process research and development projects were those that had not yet reached technology feasibility and for which no future alternative uses existed.

 

The $2.3 million of goodwill acquired from Bruker Optics in connection with the acquisition was assigned to the Company’s Bruker Optics subsidiary, currently a reportable operating segment, and will not be deductible for tax purposes since the acquisition was a tax-free acquisition.

 

On January 1, 2007, the Company acquired all of the assets of Keca Metal Products, Ltd. (“Keca”), a Texas partnership located in Spring, Texas.  The aggregate purchase price for Keca was $0.6 million and was funded with cash on hand.  Keca provides specialized machining services, primarily to Bruker Optics.  The results of Keca have been included in the Bruker Optics segment from the date of acquisition.

 

 On June 30, 2007, the Company acquired Analys-Konsult AB (“AKAB”), a distributor and service provider of scientific instrumentation based in Sweden.  The aggregate purchase price of AKAB was approximately $0.8 million, of which approximately $0.5 million was paid in cash and approximately $0.3 million was funded by the issuance of an aggregate of 29,740 restricted unregistered shares of the Company’s common stock, par value $0.01 per share, to AKAB’s shareholders.  The results of AKAB have been included in the Bruker AXS segment from the date of acquisition.

 

Pro forma financial information reflecting the Keca or AKAB acquisitions has not been presented as the impact on revenues and net income and net income per common share would not have been material.

 

4.  Provision for Income Taxes

 

The income tax provision for the three months ended September 30, 2007 was $2.1 million compared to an income tax provision of $3.5 million for the three months ended September 30, 2006, representing effective tax rates of 19.1% and 54.4%, respectively. The income tax provision for the nine months ended September 30, 2007 was $7.7 million compared to an income tax provision of $9.4 million for the nine months ended September 30, 2006, representing effective tax rates of 30.1% and 51.5%, respectively. Our effective tax rate reflects our tax provision for non-U.S. entities only, since no benefit was recognized for cumulative losses incurred in the U.S. We will maintain a full valuation allowance for our U.S. net operating losses until evidence exists that it is more likely than not that the loss carryforward amounts will be utilized to offset U.S. taxable income. Our tax rate may change over time as the amount or mix of income and taxes outside the U.S. changes. Our effective tax rate is calculated using our projected annual pre-tax income or loss and is affected by research and development tax credits, the expected level of other tax benefits, and the impact of changes to the valuation allowance, as well as changes in the mix of our pre-tax income and losses among jurisdictions with varying statutory tax rates and credits.

 

7



 

On August 14, 2007, the German Business Tax Reform 2008 was signed by the Federal President and the legislative process was finalized on August 17, 2007 with the official publication of the law.  This new legislation changes the German Federal Corporate Tax Rate from 25% to 15%.  In addition, German Trade Tax is no longer deductible from the Corporate Income Tax. The Company has analyzed the impact of these changes on its deferred tax assets and liabilities as of the date of enactment. The temporary differences that will reverse after December 31, 2007 have been adjusted to reflect the new tax rate which will become effective on January 1, 2008. As a result, the Company has recorded a net reduction to income tax expense of $2.4 million in the quarter ending September 30, 2007.

 

In July 2006, the Financial Accounting Standards Board issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes – an interpretation of FASB Statement 109 (“FIN 48”). Among other things, FIN 48 provides guidance to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing a minimum recognition threshold which income tax positions must achieve before being recognized in the financial statements. In addition, FIN 48 requires expanded annual disclosures, including a rollforward of the beginning and ending aggregate unrecognized tax benefits as well as specific detail related to tax uncertainties for which it is reasonably possible the amount of unrecognized tax benefit will significantly increase or decrease within twelve months. The Company adopted FIN 48 on January 1, 2007, and recorded a reduction to retained earnings of $751,000 effective January 1, 2007. The Company has unrecognized tax benefits of approximately $2.0 million as of January 1, 2007, of which $2.0 million, if recognized, would result in a reduction of the Company’s effective tax rate.  As of September 30, 2007, the Company does not expect any material changes to unrecognized tax positions within the next twelve months.

 

The Company recognizes penalties and interest related to unrecognized tax benefits in the provision for income taxes. As of September 30, 2007, approximately $518,000 of accrued interest related to uncertain tax positions was included in other current liabilities on our consolidated balance sheet, of which $51,000 and $153,000 was recorded during the three and nine months ended September 30, 2007, respectively.

 

The tax years 2003 to 2006 are open tax years in our major taxing jurisdictions. The Company files returns in many foreign and state jurisdictions with varying statutes of limitations.

 

5.  Equity-Based Compensation

 

In 2000, the Board of Directors adopted and the stockholders approved the 2000 Stock Option Plan. The 2000 Stock Option Plan provided for the issuance of up to 2,200,000 shares of common stock in connection with awards under the Plan. The 2000 Stock Option Plan allows a committee of the Board of Directors to grant incentive stock options, non-qualified stock options, stock appreciation rights and stock awards (including restricted stock and phantom shares). The committee has the authority to determine which employees will receive the awards, the amount of the awards and other terms and conditions of the awards. Awards granted by the committee typically vest over a period of three-to-five years.

 

On July 1, 2003, the Company’s stockholders approved an amendment and restatement of the 2000 Stock Option Plan to change the plan name and increase the number of shares available for issuance. The name of the amended plan is the Bruker BioSciences Corporation Amended and Restated 2000 Stock Option Plan. The amendment authorized 4,132,000 additional shares of common stock of the Company issuable pursuant to the plan. On June 29, 2006, the Company’s stockholders approved an increase in the number of shares available for issuance under the plan from 6,320,000 shares to 8,000,000 shares, an increase of 1,680,000 shares.

 

The total number of shares issuable under the plan is 8,000,000, all of which have been registered on Form S-8 (Reg. No. 333-47836, 333-107294 and 333-137090).

 

As of September 30, 2007, the Company’s primary types of share-based compensation related to issuances of stock options and restricted stock. The Company recorded stock-based compensation expense for the three and nine months ended September 30, 2007 and 2006 as follows (in thousands):

 

 

 

Three months ended

 

Nine months ended

 

 

 

September 30,

 

September 30,

 

 

 

2007

 

2006

 

2007

 

2006

 

 

 

 

 

 

 

 

 

 

 

Stock options

 

$

557

 

$

277

 

$

1,031

 

$

813

 

Restricted stock

 

143

 

155

 

466

 

229

 

Total stock-based compensation, pre-tax

 

700

 

432

 

1,497

 

1,042

 

Tax benefit

 

(196

)

(121

)

(419

)

(266

)

Total stock-based compensation, net of tax

 

$

504

 

$

311

 

$

1,078

 

$

776

 

 

Restricted shares of the Company’s common stock are periodically awarded to executive officers, directors and certain key employees of the Company subject to a service restriction which expires ratably over a period of three-to-five years. The restricted shares of common stock may not be sold or transferred during the restriction period. Stock compensation for restricted stock is

 

8



 

recorded based on the stock price on the grant date and charged to expense ratably through the restriction period. The following table summarizes information about restricted stock activity during the nine months ended September 30, 2007:

 

 

 

 

 

Weighted

 

 

 

Shares

 

Average

 

 

 

Subject to

 

Grant Date

 

 

 

Restriction

 

Fair Value

 

Outstanding at December 31, 2006

 

628,200

 

$

5.29

 

Granted

 

35,400

 

8.07

 

Vested

 

(129,090

)

5.34

 

Forfeited

 

(5,630

)

5.83

 

Outstanding at September 30, 2007

 

528,880

 

$

5.45

 

 

Unrecognized pretax expense of $2.1 million related to restricted stock awards is expected to be recognized over the weighted average remaining service period of 3.6 years for awards outstanding at September 30, 2007.

 

The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option-pricing model. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. Volatility and expected term assumptions are based on the Company’s historical experience. The risk-free interest rate is based on a U.S. treasury note with a maturity similar to the stock option award’s expected life. The assumptions for volatility, expected life, dividend yield and risk-free interest rate are presented in the table below:

 

 

 

2007

 

2006

 

Risk-free interest rate

 

4.52% - 4.81

%

3.80

%

Expected life

 

6.5 years

 

5 years

 

Volatility

 

82.0

%

105.0

%

Expected dividend yield

 

0

%

0

%

 

All stock options granted had an exercise price equal to the market value of the underlying common stock on the date of grant. Stock option activity for the nine months ended September 30, 2007 was as follows:

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

Weighted

 

Average

 

Aggregate

 

 

 

Shares

 

Average

 

Remaining

 

Intrinsic

 

 

 

Subject to

 

Option

 

Contractual

 

Value

 

 

 

Options

 

Price

 

Term (Yrs)

 

($’s in 000’s)

 

Outstanding at December 31, 2006

 

3,671,425

 

$

6.25

 

 

 

 

 

Granted

 

1,247,174

 

7.93

 

 

 

 

 

Exercised

 

(322,623

)

5.12

 

 

 

 

 

Forfeited

 

(45,091

)

9.84

 

 

 

 

 

Outstanding at September 30, 2007

 

4,550,885

 

$

6.75

 

4.8

 

$

11,985

 

Exercisable at September 30, 2007

 

2,653,753

 

$

6.70

 

4.3

 

$

8,236

 

 

The following table summarizes information about stock options outstanding and exercisable at September 30, 2007:

 

 

 

Options Outstanding

 

Options Exercisable

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average

 

Weighted

 

Aggregate

 

 

 

Weighted

 

Aggregate

 

 

 

 

 

Remaining

 

Average

 

Intrinsic

 

 

 

Average

 

Intrinsic

 

Range of

 

Number

 

Contractual

 

Exercise

 

Value

 

Number

 

Exercise

 

Value

 

Exercise Prices

 

Outstanding

 

Term (Yrs)

 

Price

 

($’s in 000’s)

 

Exercisable

 

Price

 

($’s in 000’s)

 

$2.12 to $4.00

 

732,448

 

4.0

 

$

3.21

 

$

4,097

 

595,454

 

$

3.18

 

$

3,344

 

$4.01 to $6.00

 

1,664,504

 

4.6

 

5.17

 

6,041

 

1,118,321

 

5.14

 

4,089

 

$6.01 to $10.00

 

1,625,584

 

7.2

 

7.67

 

1,847

 

411,629

 

6.85

 

803

 

$10.01 to $13.00

 

203,349

 

4.4

 

11.02

 

 

203,349

 

11.02

 

 

$13.01 and above

 

325,000

 

3.6

 

15.64

 

 

325,000

 

15.64

 

 

 

 

4,550,885

 

4.8

 

$

6.75

 

$

11,985

 

2,653,753

 

$

6.70

 

$

8,236

 

 

9



 

The intrinsic values above are based on the Company’s closing stock price of $8.80 on September 30, 2007. The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2007 was $5.88. Unrecognized pretax expense of $8.9 million related to stock options is expected to be recognized over the weighted average remaining service period of 3.0 years for awards outstanding at September 30, 2007.

 

6.  Inventories

 

Inventories consisted of the following as of September 30, 2007 and December 31, 2006 (in thousands):

 

 

 

September 30,

 

December 31,

 

 

 

2007

 

2006

 

Raw materials

 

$

55,008

 

$

45,361

 

Work in process

 

57,234

 

42,269

 

Demonstration units

 

19,294

 

14,678

 

Finished goods

 

52,712

 

32,196

 

Total inventories

 

$

184,248

 

$

134,504

 

 

7.  Goodwill and Other Intangible Assets

 

The following is a summary of other intangible assets subject to amortization as of  September 30, 2007 and December 31, 2006 (in thousands):

 

 

 

September 30, 2007

 

December 31, 2006

 

 

 

Useful

 

Gross

 

 

 

Net

 

Gross

 

 

 

Net

 

 

 

Lives

 

Carrying

 

Accumulated

 

Carrying

 

Carrying

 

Accumulated

 

Carrying

 

 

 

in Years

 

Amount

 

Amortization

 

Amount

 

Amount

 

Amortization

 

Amount

 

Existing technology and related patents

 

4 to 5

 

$

6,335

 

$

(2,861

)

$

3,474

 

$

6,172

 

$

(1,916

)

$

4,256

 

Customer relationships

 

5

 

1,115

 

(455

)

660

 

1,108

 

(288

)

820

 

Trade names

 

5 to 10

 

439

 

(161

)

278

 

718

 

(215

)

503

 

Total amortizable intangible assets

 

 

 

$

7,889

 

$

(3,477

)

$

4,412

 

$

7,998

 

$

(2,419

)

$

5,579

 

 

For the three months ended September 30, 2007 and 2006, the Company recorded amortization expense of approximately $0.3 million and $0.3 million, respectively, related to other amortizable intangible assets.  For the nine months ended September 30, 2007 and 2006, the Company recorded amortization expense of approximately $1.1 million and $0.6 million, respectively, related to other amortizable intangible assets.

 

The estimated future amortization expense related to other amortizable intangible assets is as follows (in thousands):

 

For the year ending December 31,

 

 

 

2007 (a)

 

$

316

 

2008

 

1,239

 

2009

 

1,210

 

2010

 

1,088

 

2011

 

510

 

Thereafter

 

49

 

Total

 

$

4,412

 

 


(a)  Amount represents estimated amortization expense for the remaining three months ending December 31, 2007.

 

The carrying amount of goodwill was $39.8 million as of September 30, 2007 and December 31, 2006, and is primarily included in the Bruker AXS segment. The Company performs its annual test for indications of impairment as of December 31st each year. The Company completed its annual test for impairment as of December 31, 2006 and determined that goodwill was not impaired at that time.

 

8.  Warranty Costs

 

The Company typically provides a one-year parts and labor warranty with the purchase of equipment. The anticipated cost for

 

10



 

this one-year warranty is accrued upon recognition of the sale and is included as a current liability on the balance sheet. The Company also offers to its customers warranty and service agreements extending beyond the initial year of warranty for a fee. These fees are recorded as deferred revenue and amortized into income over the life of the extended warranty contract.

 

Changes in the Company’s accrued warranty liability during the nine months ended September 30, 2007 were as follows (in thousands):

 

Warranty accrual at December 31, 2006

 

$

13,274

 

Accruals for warranties issued during the period

 

8,593

 

Settlements of warranty claims

 

(8,475

)

Foreign currency impact

 

789

 

Warranty accrual at September 30, 2007

 

$

14,181

 

 

9.  Line of Credit

 

On July 5, 2006, the Company issued a demand promissory note for a $40 million line of credit in the United States. On September 28, 2007, the demand promissory note was increased to $75 million. As of September 30, 2007, the line of credit was fully available. The note bears interest at the bank’s prime rate, LIBOR plus 1%, or a LIBOR advantage rate plus 1% at the request of the Company.  All of the Company’s obligations under the line of credit are secured by a pledge to the bank of 100% of the capital stock of each of the Company’s wholly-owned domestic subsidiaries, each of which also pledged a portion of the stock of certain of their foreign subsidiaries.

 

10.  Employee Benefit Plans

 

The Company has a defined benefit retirement plan that covers substantially all employees of the Bruker AXS German subsidiary who were employed as of September 30, 1997. The plan provides pension benefits based upon final average salary and years of service.

 

The net periodic pension benefit cost includes the following components during the three and nine months ended September 30, 2007 and 2006 (in thousands):

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

 

September 30,

 

September 30,

 

 

 

2007

 

2006

 

2007

 

2006

 

Components of net periodic pension benefit cost

 

 

 

 

 

 

 

 

 

Service cost

 

$

278

 

$

177

 

$

837

 

$

522

 

Interest cost

 

127

 

98

 

380

 

290

 

Amortization

 

(4

)

(4

)

(12

)

(12

)

Net periodic benefit cost

 

$

401

 

$

271

 

$

1,205

 

$

800

 

 

To date, the Company has not funded the defined benefit plan and is not required to make contributions during the remainder of 2007.

 

11.  Earnings Per Share

 

Basic earnings per share is calculated by dividing net earnings by the weighted-average number of common shares outstanding during the period.  Restricted stock is not included in the calculation of basic EPS until the time-based restriction has lapsed. Except where the result would be antidilutive, the diluted earnings per share computation includes the effect of potential shares, shares which would be issuable upon the exercise of outstanding stock options or outstanding restricted stock issuable when the restrictions lapse, reduced by the number of shares which are assumed to be purchased by the Company from the resulting proceeds at the average market price during the period.

 

The following table sets forth the computation of basic and diluted average shares outstanding for the three and nine months ended September 30, 2007 and 2006 (in thousands):

 

11



 

 

 

Three Months Ended

 

Nine Months Ended

 

 

 

September 30,

 

September 30,

 

 

 

2007

 

2006

 

2007

 

2006

 

Net income, as reported

 

$

8,664

 

$

2,976

 

$

17,510

 

$

8,773

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding:

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding - basic

 

104,377

 

102,038

 

103,806

 

101,635

 

Effect of dilutive securities:

 

 

 

 

 

 

 

 

 

Stock options and restricted stock

 

2,302

 

666

 

2,678

 

455

 

Weighted average shares outstanding - diluted

 

106,679

 

102,704

 

106,484

 

102,090

 

Net income per share - basic

 

$

0.08

 

$

0.03

 

$

0.17

 

$

0.09

 

Net income per share - diluted

 

$

0.08

 

$

0.03

 

$

0.16

 

$

0.09

 

 

The total anti-diluted shares outstanding for the nine months ended September 30, 2007 and 2006 were 640,000 and 1,027,000, respectively.

 

12. Interest and Other Income (Expense), Net

 

The components of interest and other income (expense), net, were as follows for the three and nine months ended September 30, 2007 and 2006 (in thousands):

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

 

September 30,

 

September 30,

 

 

 

2007

 

2006

 

2007

 

2006

 

Interest income

 

$

235

 

$

294

 

$

909

 

$

1,939

 

Interest expense

 

(386

)

(762

)

(1,294

)

(1,556

)

Exchange losses on foreign currency transactions

 

(1,078

)

(68

)

(1,680

)

(1,165

)

Appreciation of the fair value of derivative financial instruments

 

179

 

118

 

759

 

3,893

 

Other

 

431

 

(73

)

481

 

411

 

Interest and other income (expense), net

 

$

(619

)

$

(491

)

$

(825

)

$

3,522

 

 

13.  Comprehensive Income

 

Comprehensive income refers to revenues, expenses, gains and losses that under accounting principles generally accepted in the United States of America are included in other comprehensive income, but excluded from net income as these amounts are recorded directly as an adjustment to stockholders’ equity, net of tax.  The following is a summary of comprehensive income for the three and nine months ended September 30, 2007 and 2006 (in thousands):

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

 

September 30,

 

September 30,

 

 

 

2007

 

2006

 

2007

 

2006

 

Net income

 

$

8,664

 

$

2,976

 

$

17,510

 

$

8,773

 

Foreign currency translation adjustments

 

7,252

 

(249

)

9,950

 

8,265

 

Total comprehensive income

 

$

15,916

 

$

2,727

 

$

27,460

 

$

17,038

 

 

14.  Commitments and Contingencies

 

Lawsuits, claims and proceedings of a nature considered normal to its businesses may be pending from time to time against the Company. The Company believes the outcome of these proceedings, if any, will not have a material impact on the Company’s financial position or results of operations.

 

15.  Letters of Credit and Guarantees

 

As of September 30, 2007 and December 31, 2006, the Company had bank guarantees of $11.6 million and $9.1 million,

 

12



 

respectively, for its customer advances. These bank guarantees affect the availability of the Company’s lines of credit.

 

16.  Business Segment Information

 

SFAS No. 131, Disclosures about Segments of an Enterprise and Related Information (“SFAS 131”), establishes standards for reporting information about reportable segments in financial statements of public business enterprises. SFAS 131 also establishes standards for related disclosures about products and services, geographic areas and major customers. The Company reports financial results on the basis of three reportable segments: Bruker AXS, Bruker Daltonics and Bruker Optics. Bruker AXS manufactures and distributes advanced X-ray instrumentation and spark-OES instrumentation used in non-destructive molecular and elemental analysis in academic, research and industrial applications.  Bruker Daltonics manufactures and distributes mass spectrometry instruments that can be integrated and used with other analytical instruments. Bruker Optics manufactures and distributes infrared and Raman molecular spectroscopy instruments and solutions that can be used in analytical and research applications. Bruker BioSciences Corporation, the parent company of Bruker AXS, Bruker Daltonics and Bruker Optics, is the corporate entity that principally incurs certain public company costs.

 

Selected reportable segment financial information for the three and nine months ended September 30, 2007 and 2006 is presented below (in thousands):

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

 

September 30,

 

September 30,

 

 

 

2007

 

2006

 

2007

 

2006

 

Revenue:

 

 

 

 

 

 

 

 

 

Bruker AXS

 

$

59,969

 

$

47,015

 

$

165,212

 

$

123,985

 

Bruker Daltonics

 

46,486

 

36,301

 

126,176

 

113,660

 

Bruker Optics

 

28,682

 

24,517

 

80,705

 

69,373

 

Eliminations (a)

 

(3,494

)

(2,963

)

(8,260

)

(6,809

)

Total

 

$

131,643

 

$

104,870

 

$

363,833

 

$

300,209

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss):

 

 

 

 

 

 

 

 

 

Bruker AXS

 

$

6,164

 

$

2,836

 

$

14,444

 

$

5,496

 

Bruker Daltonics

 

2,885

 

1,242

 

4,167

 

5,707

 

Bruker Optics

 

4,311

 

5,083

 

11,816

 

9,526

 

Eliminations (a)

 

(185

)

459

 

(203

)

100

 

Corporate

 

(1,718

)

(2,636

)

(3,979

)

(6,105

)

Total

 

$

11,457

 

$

6,984

 

$

26,245

 

$

14,724

 

 


(a) represents transactions between segments which are eliminated in consolidation.

 

17.  Recent Accounting Pronouncements

 

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Liabilities, Including an amendment of FASB Statement No. 115 (“SFAS 159”). This Statement permits entities to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value. SFAS 159 is effective as of the beginning of fiscal 2008. The Company has not yet assessed the effect, if any, that adoption of SFAS 159 will have on its results of operations and financial position.

 

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (“SFAS 157”). This Statement is effective for financial statements issued for fiscal years beginning after November 15, 2007. SFAS 157 provides a common fair value hierarchy for companies to follow in determining fair value measurements in the preparation of financial statements and expands disclosure requirements relating to how such fair value measurements were developed. SFAS 157 clarifies the principle that fair value should be based on the assumptions that the marketplace would use when pricing an asset or liability, rather than company specific data. The Company is currently assessing the impact that SFAS 157 will have on its results of operations and financial position.

 

13



 

ITEM 2:  Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion of our financial condition and results of operations should be read in conjunction with our interim condensed consolidated financial statements and the notes to those statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q, and in conjunction with the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2006.

 

Statements contained in Management’s Discussion and Analysis of Financial Condition and Results of Operations which express that we “believe”, “anticipate”, “expect” or “plan to”, as well as other statements which are not historical fact, are forward-looking statements within the meaning of the Private Securities Litigation Act of 1995. Actual events or results may differ materially from those set forth in forward-looking statements. Certain factors that might cause such a difference are discussed in “Factors Affecting Our Business, Operating Results and Financial Condition” set forth in our Annual Report on Form 10-K for the year ended December 31, 2006.

 

OVERVIEW

 

The following management’s discussion and analysis of financial condition and results of operations (MD&A) describes the principal factors affecting the results of our operations, financial condition, and changes in financial condition, as well as our critical accounting policies and estimates. MD&A is organized as follows:

 

                     Executive overview. This section provides a general description and history of our business, a brief discussion of our reportable segments and significant recent developments in our business.

 

                     Critical accounting policies and estimates. This section discusses the accounting estimates that are considered important to our financial condition and results of operations and require us to exercise subjective or complex judgments in their application.

 

                     Results of operations. This section provides our analysis of the significant line items in our consolidated statement of operations for the three and nine months ended September 30, 2007 compared to the three and nine months ended September 30, 2006.

 

                     Liquidity and capital resources. This section provides an analysis of our liquidity and cash flow and a discussion of our outstanding debt and commitments.

 

EXECUTIVE OVERVIEW

 

Bruker BioSciences and its wholly-owned subsidiaries design, manufacture, market and service proprietary life science and materials research systems based on mass spectrometry core technology platforms, X-ray technologies, optical emission spectroscopy (OES) technologies, and molecular spectroscopy technologies. We also manufacture and distribute a broad range of field analytical systems for chemical, biological, radiological and nuclear, or CBRN, detection. We report financial results on the basis of three reportable segments: Bruker AXS, Bruker Daltonics and Bruker Optics.

 

Bruker AXS primarily engages in the business of manufacturing and distributing advanced instrumentation and automated solutions based on X-ray and spark-OES technologies with the purpose of addressing the needs of our customers in the discovery of new drugs, drug targets and advanced materials, as well as industrial QA/QC applications. Typical customers of Bruker AXS’ products and solutions include biotechnology and pharmaceutical companies, semiconductor industries, chemical, cement, metals and petroleum companies, raw material manufacturers, and academic and government research institutions. Bruker Daltonics is a leading manufacturer of innovative mass spectrometry-based instruments and accessories used by pharmaceutical, biotechnology, proteomics and molecular diagnostics companies, academic institutions, and government agencies in their research that can also be integrated and used along with other analytical instruments. Bruker Daltonics also manufactures and distributes a broad range of field analytical systems for CBRN detection. Bruker Optics is a leading developer, manufacturer and provider of research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technology. Typical customers of Bruker Optics’ products and solutions include pharmaceutical and biotechnology companies, cement and petroleum companies, food, beverage and agricultural industries, and academic and government research institutions.

 

We maintain major technical and manufacturing centers in Europe, North America and Japan. We have sales offices located throughout the world and our corporate headquarters is located in Billerica, Massachusetts. Our business strategy is to capitalize on our proven ability to innovate and generate rapid revenue growth, both organically and through acquisitions. Our revenue growth strategy, combined with improvements to our gross profit margins over time and increased leverage on our operating expenses, are expected to enhance our operating margins and improve our earnings in the future.

 

For the nine months ended September 30, 2007, our revenues grew by 21% to $363.8 million, with acquisitions contributing approximately 3% and foreign exchange rate changes contributing approximately 5% of this growth. We continue to focus on improving our profitability and our gross profit margins improved from 45.1% during the nine months ended

 

14



 

September 30, 2006 to 46.0% for the nine months ended September 30, 2007, reflecting volume leverage, contributions from our recently integrated acquisitions and improvements realized from ongoing gross profit margin improvement programs.  We continue to invest in incremental sales and marketing initiatives, primarily headcount increases, which has resulted in our sales and marketing expenses as a percentage of product and service revenue increasing year-over-year.  We expect these investments to result in increased revenues in future periods.  Our increased revenues did enable us to leverage both general and administrative and research and development expenses as a percentage of revenue during the nine months ended September 30, 2007 compared to the comparable period in 2006.

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates and judgments, including those related to revenue recognition, allowance for doubtful accounts, inventories, goodwill, long-lived assets, warranty costs and income taxes. We base our estimates and judgments on historical experience, current market and economic conditions, our observance of industry trends and other assumptions that we believe are reasonable and form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

 

We believe the following critical accounting policies to be both those most important to the portrayal of our financial condition and those that require the most subjective judgment.

 

                     Revenue recognition. We recognize revenue from system sales when persuasive evidence of an arrangement exists, the price is fixed or determinable, title and risk of loss has been transferred to the customer and collectibility of the resulting receivable is reasonably assured. Title and risk of loss is generally transferred to the customer upon receipt of a signed customer acceptance form for a system that has been shipped, installed, and for which the customer has been trained. As a result, the timing of customer acceptance or readiness could cause our reported revenues to differ materially from expectations. When products are sold through an independent distributor, a strategic distribution partner or an unconsolidated affiliated distributor, which assumes responsibility for installation, we recognize the system sale when the product has been shipped and title and risk of loss have been transferred. Our distributors do not have price protection rights or rights to return; however, our products are generally warranted to be free from defect for a period of one year. Revenue is deferred until cash is received when a significant portion of the fee is due over one year after delivery, installation and acceptance of a system. For arrangements with multiple elements, we recognize revenue for each element based on the fair value of the element, provided all other criteria for revenue recognition have been met. The fair value for each element provided in multiple element arrangements is typically determined by referencing historical pricing policies when the element is sold separately. Changes in our ability to establish the fair value for each element in multiple element arrangements could affect the timing of revenue recognition. Revenue from accessories and parts is recognized upon shipment and service revenue is recognized as the services are performed. We record grant revenue from government contracts by deferring any up-front payments received and recording the revenue for research and development activities systematically over the life of the contract as the services are provided.

 

                     Warranty costs. We normally provide a one-year parts and labor warranty with the purchase of equipment. The anticipated cost for this one-year warranty is accrued upon recognition of the sale and is included as a current liability on the balance sheet. Although our facilities undergo quality assurance and testing procedures throughout the production process, our warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Although our actual warranty costs have historically been consistent with expectations, to the extent warranty claim activity or costs associated with servicing those claims differ from our estimates, revisions to the warranty accrual may be required.

 

                     Inventories. Inventories are stated at the lower of cost or market, with cost determined by the first-in, first-out method. We maintain an allowance for excess and obsolete inventory to reflect the expected un-saleable or un-refundable inventory based on an evaluation of slow moving products. If ultimate usage or demand varies significantly from expected usage or demand, additional write-downs may be required, resulting in a charge to operations.

 

                    Goodwill, other intangible assets, and other long-lived assets. We perform an evaluation of whether goodwill is impaired annually or when events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Fair value is determined using market comparables for similar businesses or forecasts of discounted future cash flows. We also review other intangible assets and other long-lived assets when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. Should the fair value of our long-lived assets decline because of reduced operating performance, market declines, or other indicators of impairment, a charge to operations for impairment may be necessary.

 

                     Allowance for doubtful accounts. We maintain allowances for doubtful accounts for estimated losses resulting from the

 

15



 

inability of our customers to pay amounts due. If the financial condition of our customers were to deteriorate, reducing their ability to make payments, additional allowances would be required and would result in a charge to operations.

 

                     Income taxes. We estimate the degree to which tax assets and loss carryforwards will result in a benefit based on expected profitability by tax jurisdiction, and provide a valuation allowance for tax assets and loss carryforwards that we believe will more likely than not go unused. If it becomes more likely than not that a tax asset or loss carryforward will be used for which a reserve has been provided, we reverse the related valuation allowance. If our actual future taxable income by tax jurisdiction differs from estimates, additional allowances or reversals of reserves may be necessary.

 

Results of Operations

 

Three months ended September 30, 2007 compared to the three months ended September 30, 2006

 

Revenue

 

The following table presents revenue, change in revenue and revenue growth by reportable segment for the three months ended September 30, 2007 and 2006 (dollars in thousands):

 

 

 

 

 

 

 

 

 

Percentage

 

 

 

2007

 

2006

 

$ Change

 

Change

 

Bruker AXS

 

$

59,969

 

$

47,015

 

$

12,954

 

27.6

%

Bruker Daltonics

 

46,486

 

36,301

 

10,185

 

28.1

%

Bruker Optics

 

28,682

 

24,517

 

4,165

 

17.0

%

Eliminations (a)

 

(3,494

)

(2,963

)

(531

)

 

 

Total Revenue

 

$

131,643

 

$

104,870

 

$

26,773

 

25.5

%

 


(a) represents revenue recorded on transactions between segments which is eliminated in consolidation.

 

Bruker AXS’ revenue increased by $13.0 million, or 27.6%, to $60.0 million for the three months ended September 30, 2007 compared to $47.0 million for the comparable period in 2006. Included in this change in revenue is approximately $2.2 million from the impact of foreign exchange. Excluding the effect of foreign exchange, revenue increased by 22.9%. The increase in revenue is attributable to an increase in x-ray diffraction and x-ray fluorescence system sales, to higher other system revenue and aftermarket revenue, and to the businesses acquired in the second half of 2006, which represented approximately 5% of the revenue growth. Other system revenue relates primarily to the distribution of products not manufactured by Bruker AXS. X-ray systems, other system and aftermarket revenue as a percentage of Bruker AXS’ product and service revenue were as follows during the three months ended September 30, 2007 and 2006 (dollars in thousands):

 

 

 

2007

 

2006

 

 

 

 

 

Percentage of

 

 

 

Percentage of

 

 

 

 

 

Segment Product

 

 

 

Segment Product

 

 

 

Revenue

 

and Service Revenue

 

Revenue

 

and Service Revenue

 

X-Ray Systems

 

$

41,065

 

68.5

%

$

32,129

 

68.4

%

Other System Revenue

 

4,540

 

7.6

%

3,534

 

7.5

%

Bruker AXS Aftermarket

 

14,364

 

23.9

%

11,352

 

24.1

%

Total Product and Service Revenue

 

$

59,969

 

100

%

$

47,015

 

100

%

 

Bruker Daltonics’ revenue increased by $10.2 million, or 28.1%, to $46.5 million for the three months ended September 30, 2007 compared to $36.3 million for the comparable period in 2006. Included in this change in revenue is approximately $2.2 million from the impact of foreign exchange. Excluding the effect of the foreign exchange benefit, revenue increased by 21.9%. The increase in revenue excluding the effect of foreign exchange is a result of an increase in direct life science system sales, CBRN detection systems and aftermarket revenue, partially offset by reduced OEM sales for certain life science systems year-over-year.  Aftermarket revenues include accessory sales, consumables, training and services. Included in other revenue during the three months ended September 30, 2007 and 2006 are grant revenues for early-stage research and development projects funded by the German government. Life science systems, CBRN detection systems and aftermarket revenue as a percentage of Bruker Daltonics’ product and service revenue were as follows during the three months ended September 30, 2007 and 2006 (dollars in thousands):

 

16



 

 

 

2007

 

2006

 

 

 

 

 

Percentage of

 

 

 

Percentage of

 

 

 

 

 

Segment Product

 

 

 

Segment Product

 

 

 

Revenue

 

and Service Revenue

 

Revenue

 

and Service Revenue

 

Life Science Systems

 

$

31,244

 

67.5

%

$

26,381

 

73.2

%

CBRN Detection Systems

 

5,328

 

11.5

%

2,175

 

6.0

%

Bruker Daltonics Aftermarket

 

9,723

 

21.0

%

7,487

 

20.8

%

Product and Service Revenue

 

46,295

 

100

%

36,043

 

100

%

Grant Revenue

 

191

 

 

 

258

 

 

 

Total Revenue

 

$

46,486

 

 

 

$

36,301

 

 

 

 

Bruker Optics’ revenue increased by $4.2 million, or 17.0%, to $28.7 million for the three months ended September 30, 2007 compared to $24.5 million for the comparable period in 2006. Included in this change in revenue is approximately $1.3 million from the impact of foreign exchange. Excluding the effect of foreign exchange, revenue increased by 11.9%. The increase in revenue excluding the effect of foreign exchange is primarily due to higher sales of molecular spectroscopy systems year-over-year, partially offset by reduced revenues associated with our order with the Chinese State Food and Drug Administration. For the three months ended September 30, 2007, we recognized $0.8 million in revenue from our order with the Chinese State Food and Drug Administration, compared to $2.4 million in revenue from this order in the same period in 2006. Aftermarket revenues include accessory sales, consumables, training and services. Other system revenue relates primarily to the distribution of products not manufactured by Bruker Optics. Molecular spectroscopy systems, other system and aftermarket revenue as a percentage of Bruker Optics’ product and service revenue were as follows during the three months ended September 30, 2007 and 2006 (dollars in thousands):

 

 

 

2007

 

2006

 

 

 

 

 

Percentage of

 

 

 

Percentage of

 

 

 

 

 

Segment Product

 

 

 

Segment Product

 

 

 

Revenue

 

and Service Revenue

 

Revenue

 

and Service Revenue

 

 

 

 

 

 

 

 

 

 

 

Molecular Spectroscopy Systems

 

$

22,047

 

76.9

%

$

18,694

 

76.2

%

Other System Revenue

 

1,723

 

6.0

%

1,524

 

6.3

%

Bruker Optics Aftermarket

 

4,912

 

17.1

%

4,299

 

17.5

%

Total Product and Service Revenue

 

$

28,682

 

100

%

$

24,517

 

100

%

 

Cost of Revenue

 

The following table presents cost of product and service revenue and gross profit margins on product and service revenue by reportable segment for the three months ended September 30, 2007 and 2006 (dollars in thousands):

 

 

 

2007

 

2006

 

 

 

Cost of

 

Gross Profit

 

Cost of

 

Gross Profit

 

 

 

Revenue

 

Margin

 

Revenue

 

Margin

 

Bruker AXS

 

$

32,294

 

46.2

%

$

28,944

 

38.5

%

Bruker Daltonics

 

26,425

 

42.9

%

21,441

 

40.5

%

Bruker Optics

 

14,295

 

50.1

%

11,244

 

54.0

%

Eliminations (a)

 

(3,204

)

 

 

(2,942

)

 

 

Total Cost of Revenue

 

$

69,810

 

46.9

%

$

58,687

 

43.9

%

 


(a)          represents the cost of revenues between segments which is eliminated in consolidation.

 

Bruker AXS’ cost of product and service revenue for the three months ended September 30, 2007 was $32.3 million, resulting in a gross profit margin of 46.2%, compared to cost of product and service revenue of $28.9 million, or a gross profit margin of 38.5%, for the comparable period in 2006. The increase in gross profit margin is primarily attributable to better capacity utilization as a result of increased revenues year-over-year and the realization of benefits from various ongoing gross profit margin improvement programs, partially offset by lower gross profit margins realized on other system revenues.

 

Bruker Daltonics’ cost of product and service revenue for the three months ended September 30, 2007 was $26.4 million, resulting in a gross profit margin of 42.9%, compared to cost of product and service revenue of $21.4 million, or a gross profit margin of 40.5%, for the comparable period in 2006. The increase in gross profit margin is primarily attributable to increased sales of our CBRN detection systems, and a decrease in OEM life science system sales, which typically have lower margins than direct life science

 

17



 

system sales.

 

Bruker Optics’ cost of product and service revenue for the three months ended September 30, 2007 was $14.3 million, resulting in a gross profit margin of 50.1%, compared to cost of product and service revenue of $11.2 million, or a gross profit margin of 54.0%, for the comparable period in 2006. The decrease in gross profit margin is primarily attributable to reduced revenues from our order with the Chinese State Food and Drug Administration.

 

Sales and Marketing

 

The following table presents sales and marketing expense and sales and marketing expense as a percentage of product and service revenue by reportable segment for the three months ended September 30, 2007 and 2006 (dollars in thousands):

 

 

 

2007

 

2006

 

 

 

 

 

Percentage of

 

 

 

Percentage of

 

 

 

Sales and

 

Segment Product

 

Sales and

 

Segment Product

 

 

 

Marketing

 

and Service Revenue

 

Marketing

 

and Service Revenue

 

Bruker AXS

 

$

11,945

 

19.9

%

$

7,956

 

16.9

%

Bruker Daltonics

 

8,270

 

17.9

%

5,795

 

16.1

%

Bruker Optics

 

6,842

 

23.9

%

5,312

 

21.7

%

Total Sales and Marketing

 

$

27,057

 

20.6

%

$

19,063

 

18.2

%

 

Bruker AXS’ sales and marketing expense for the three months ended September 30, 2007 increased to $11.9 million, or 19.9% of product and service revenue, from $8.0 million, or 16.9% of product and service revenue for the comparable period in 2006. The increase in sales and marketing expense is primarily attributable to increased headcount related to the acquisitions completed during the second half of 2006 and higher commissions on increased revenues from our core business year-over-year.

 

Bruker Daltonics’ sales and marketing expense for the three months ended September 30, 2007 increased to $8.3 million, or 17.9% of product and service revenue, from $5.8 million, or 16.1% of product and service revenue for the comparable period in 2006. The increase in sales and marketing expense is attributable to incremental investments in various sales and marketing initiatives, primarily related to an increase in field sales personnel, product specialists and applications resources.

 

Bruker Optics’ sales and marketing expense for the three months ended September 30, 2007 increased to $6.8 million, or 23.9% of product and service revenue, from $5.3 million, or 21.7% of product and service revenue for the comparable period in 2006. The increase in sales and marketing expense is primarily attributable to higher commissions on increased revenues and new order bookings year-over-year, particularly in our Asia-Pacific operations.

 

General and Administrative

 

The following table presents general and administrative expense and general and administrative expense as a percentage of product and service revenue by reportable segment for the three months ended September 30, 2007 and 2006 (dollars in thousands):

 

 

 

2007

 

2006

 

 

 

 

 

Percentage of

 

 

 

Percentage of

 

 

 

General and

 

Segment Product

 

General and

 

Segment Product

 

 

 

Administrative

 

and Service Revenue

 

Administrative

 

and Service Revenue

 

Bruker AXS

 

$

3,846

 

6.4

%

$

3,309

 

7.0

%

Bruker Daltonics

 

2,285

 

4.9

%

2,048

 

5.7

%

Bruker Optics

 

1,407

 

4.9

%

1,104

 

4.5

%

Corporate

 

1,018

 

 

 

778

 

 

 

Total General and Administrative

 

$

8,556

 

6.5

%

$

7,239

 

6.9

%

 

Bruker AXS’ general and administrative expenses for the three months ended September 30, 2007 increased to $3.8 million, or 6.4% of product and service revenue, from $3.3 million, or 7.0% of product and service revenue for the comparable period in 2006. The increase in general and administrative expenses is primarily due to modest increases in headcount to support increased business activities and to intangible asset amortization associated with the acquisitions completed during the second half of 2006.

 

Bruker Daltonics’ general and administrative expense for the three months ended September 30, 2007 increased to $2.3 million, or 4.9% of product and service revenue, from $2.0 million, or 5.7% of product and service revenue for the comparable

 

18



 

period of 2006. The increase in general and administrative expenses is primarily attributable to changes in foreign currencies year-over-year.

 

Bruker Optics’ general and administrative expenses for the three months ended September 30, 2007 increased to $1.4 million, or 4.9% of product and service revenue, from $1.1 million, or 4.5% of product and service revenue for the comparable period of 2006. The increase in general and administrative expenses is primarily attributable to modest headcount increases and to changes in foreign currencies year-over-year, primarily the Euro.

 

Corporate general and administrative expense for the three months ended September 30, 2007 increased to $1.0 million from $0.8 million for the comparable period of 2006. The increase is primarily attributable to increased business development activities. Corporate general and administrative expense represents expenses associated with being a public company not allocated to our reportable segments, including legal fees, audit and consulting fees, salaries and filing fees.

 

Research and Development

 

The following table presents research and development expense and research and development expense as a percentage of product and service revenue by reportable segment for the three months ended September 30, 2007 and 2006 (dollars in thousands):

 

 

 

2007

 

2006

 

 

 

 

 

Percentage of

 

 

 

Percentage of

 

 

 

Research and

 

Segment Product

 

Research and

 

Segment Product

 

 

 

Development

 

and Service Revenue

 

Development

 

and Service Revenue

 

Bruker AXS

 

$

5,901

 

9.8

%

$

4,100

 

8.7

%

Bruker Daltonics

 

6,824

 

14.7

%

5,921

 

16.4

%

Bruker Optics

 

2,038

 

7.1

%

1,915

 

7.8

%

Total Research and Development

 

$

14,763

 

11.2

%

$

11,936

 

11.4

%

 

Bruker AXS’ research and development expense for the three months ended September 30, 2007 increased to $5.9 million, or 9.8% of product and service revenue, from $4.1 million, or 8.7% of product and service revenue for the comparable period in 2006. The increase in research and development expense is primarily attributable to an increase in materials purchases and an increase in headcount resulting from the acquisitions completed during the second half of 2006.

 

Bruker Daltonics’ research and development expense for the three months ended September 30, 2007 increased to $6.8 million, or 14.7% of product and service revenue, from $5.9 million, or 16.4% of product and service revenue for the comparable period in 2006. The increase in research and development expense is primarily attributable to an increase in materials purchases and to changes in foreign currencies year-over-year, primarily the Euro, as a majority of research and development is performed in Germany.

 

Bruker Optics’ research and development expense for the three months ended September 30, 2007 increased to $2.0 million, or 7.1% of product and service revenue, from $1.9 million, or 7.8% of product and service revenue for the comparable period in 2006. The increase in research and development expense is primarily attributable to changes in foreign currencies year-over-year, primarily the Euro, as a majority of research and development is performed in Germany, partially offset by a decrease in materials purchases.

 

Acquisition Related Charges

 

On April 18, 2006, we announced that we had entered into a definitive agreement to acquire all of the stock of molecular spectroscopy company Bruker Optics. The acquisition of Bruker Optics was approved by our shareholders on June 29, 2006 and was subsequently completed on July 1, 2006. This acquisition represented a business combination of companies under common control due to a majority ownership by individuals of both Bruker BioSciences and Bruker Optics and, as a result, transaction costs have been expensed as incurred rather than being included in the purchase price allocation. During the third quarter of 2006, we incurred acquisition related charges totaling $1.0 million, which consisted of investment banking and legal fees.

 

Interest and Other Income (Expense), Net

 

Interest and other income (expense), net, during the three months ended September 30, 2007 was $(0.6) million, compared to $(0.5) million during the three months ended September 30, 2006. During the three months ended September 30, 2007, the major components within interest and other income (expense), net, were net interest expense of $(0.2) million, losses on foreign currency transactions of $(1.1) million and the appreciation of the fair value of derivative financial instruments of $0.2 million. During the three months ended September 30, 2006, the major components within interest and other income (expense), net, were net interest expense of $(0.5) million, losses on foreign currency transactions of $(0.1) million and the appreciation of the fair value of derivative financial instruments of $0.1 million.

 

19



 

Provision for Income Taxes

 

The income tax provision for the three months ended September 30, 2007 was $2.1 million compared to an income tax provision of $3.5 million for the three months ended September 30, 2006, representing effective tax rates of 19.1% and 54.4%, respectively. The lower effective tax rate in the third quarter of 2007 compared to the third quarter of 2006 was primarily due to new tax legislation in Germany enacted in the third quarter of 2007. The Company has analyzed the impact of these changes on its deferred tax assets and liabilities as of the date of enactment. The temporary differences that will reverse after December 31, 2007 have been adjusted to reflect the new tax rate which will become effective on January 1, 2008. As a result, the Company has recorded a net reduction to income tax expense of $2.4 million in the quarter ending September 30, 2007. Our effective tax rate is calculated using our projected annual pre-tax income or loss and is affected by research and development tax credits, the expected level of other tax benefits, and the impact of changes to the valuation allowance, as well as changes in the mix of our pre-tax income and losses among jurisdictions with varying statutory tax rates and credits.

 

Minority Interest in Consolidated Subsidiaries

 

Minority interest in consolidated subsidiaries for the three months ended September 30, 2007 was $0.1 million compared to $(18,000) in the comparable period of 2006. The minority interest in subsidiaries represents the minority shareholders’ proportionate share of net income of those subsidiaries for the three months ended September 30, 2007 and 2006. For the three months ended September 30, 2007 and 2006, the minority interest relates to our two majority-owned subsidiaries, Incoatec GmbH and Bruker Baltic Ltd.

 

Nine months ended September 30, 2007 compared to the nine months ended September  30, 2006

 

Revenue

 

The following table presents revenue, change in revenue and revenue growth by reportable segment for the nine months ended September 30, 2007 and 2006 (dollars in thousands):

 

 

 

2007

 

2006

 

$ Change

 

Percentage
Change

 

Bruker AXS

 

$

165,212

 

$

123,985

 

$

41,227

 

33.3

%

Bruker Daltonics

 

126,176

 

113,660

 

12,516

 

11.0

%

Bruker Optics

 

80,705

 

69,373

 

11,332

 

16.3

%

Eliminations (a)

 

(8,260

)

(6,809

)

(1,451

)

 

 

Total Revenue

 

$

363,833

 

$

300,209

 

$

63,624

 

21.2

%

 


(a)   represents revenue recorded on transactions between segments which is eliminated in consolidation.

 

Bruker AXS’ revenue increased by $41.2 million, or 33.3%, to $165.2 million for the nine months ended September 30, 2007 compared to $124.0 million for the comparable period in 2006. Included in this change in revenue is approximately $6.0 million from the impact of foreign exchange. Excluding the effect of foreign exchange, revenue increased by 28.4%. The increase in revenue is attributable to an increase in x-ray diffraction and x-ray fluorescence system sales, to higher other system revenue and higher aftermarket revenue, and to the businesses acquired in the second half of 2006, which represented approximately 8% of the revenue growth. Other system revenue relates primarily to the distribution of products not manufactured by Bruker AXS. X-ray systems, other system and aftermarket revenue as a percentage of Bruker AXS’ product and service revenue were as follows during the nine months ended September 30, 2007 and 2006 (dollars in thousands):

 

 

 

2007

 

2006

 

 

 

 

 

Percentage of

 

 

 

Percentage of

 

 

 

 

 

Segment Product

 

 

 

Segment Product

 

 

 

Revenue

 

and Service Revenue

 

Revenue

 

and Service Revenue

 

X-Ray Systems

 

$

111,518

 

67.5

%

$

83,405

 

67.3

%

Other System Revenue

 

13,965

 

8.5

%

6,221

 

5.0

%

Bruker AXS Aftermarket

 

39,729

 

24.0

%

34,359

 

27.7

%

Total Product and Service Revenue

 

$

165,212

 

100

%

$

123,985

 

100

%

 

Bruker Daltonics’ revenue increased by $12.5 million, or 11.0%, to $126.2 million for the nine months ended September 30, 2007 compared to $113.7 million for the comparable period in 2006. Included in this change in revenue is approximately $6.1 million from the impact of foreign exchange. Excluding the effect of the foreign exchange benefit, revenue increased by 5.7%. The increase in revenue excluding the effect of foreign exchange is a result of increased direct sales of life science systems, CBRN detection systems, and aftermarket revenue year-over-year, partially offset by reduced OEM sales for certain life

 

20



 

science systems and substantially reduced grant revenue. Aftermarket revenues include accessory sales, consumables, training and services. Included in other revenue during the nine months ended September 30, 2007 and 2006 are grant revenues for early-stage research and development projects funded by the German government. Life science systems, CBRN detection systems and aftermarket revenue as a percentage of Bruker Daltonics’ product and service revenue were as follows during the nine months ended September 30, 2007 and 2006 (dollars in thousands):

 

 

 

2007

 

2006

 

 

 

 

 

Percentage of

 

 

 

Percentage of

 

 

 

 

 

Segment Product

 

 

 

Segment Product

 

 

 

Revenue

 

and Service Revenue

 

Revenue

 

and Service Revenue

 

Life Science Systems

 

$

86,517

 

68.8

%

$

85,982

 

76.4

%

CBRN Detection Systems

 

12,986

 

10.3

%

5,591

 

5.0

%

Bruker Daltonics Aftermarket

 

26,252

 

20.9

%

20,952

 

18.6

%

Product and Service Revenue

 

125,755

 

100

%

112,525

 

100

%

Grant Revenue

 

421

 

 

 

1,135

 

 

 

Total Revenue

 

$

126,176

 

 

 

$

113,660

 

 

 

 

Bruker Optics’ revenue increased by $11.3 million, or 16.3%, to $80.7 million for the nine months ended September 30, 2007 compared to $69.4 million for the comparable period in 2006. Included in this change in revenue is approximately $3.3 million from the impact of foreign exchange. Excluding the effect of foreign exchange, revenue increased by 11.6%. The increase in revenue excluding the effect of foreign exchange is due to higher sales of molecular spectroscopy systems year-over-year and higher aftermarket sales, partially offset by reduced revenues associated with our order with the Chinese State Food and Drug Administration. For the nine months ended September 30, 2007, we recognized $4.9 million in revenue from our order with the Chinese State Food and Drug Administration compared to $6.1 million in revenues from this order in the same period in 2006. Aftermarket revenues include accessory sales, consumables, training and services. Other system revenue relates primarily to the distribution of products not manufactured by Bruker Optics. Molecular spectroscopy systems, other system and aftermarket revenue as a percentage of Bruker Optics’ product and service revenue were as follows during the nine months ended September 30, 2007 and 2006 (dollars in thousands):

 

 

 

2007

 

2006

 

 

 

 

 

Percentage of

 

 

 

Percentage of

 

 

 

 

 

Segment Product

 

 

 

Segment Product

 

 

 

Revenue

 

and Service Revenue

 

Revenue

 

and Service Revenue

 

Molecular Spectroscopy Systems

 

$

61,386

 

76.1

%

$

52,396

 

75.5

%

Other System Revenue

 

5,447

 

6.7

%

5,467

 

7.9

%

Bruker Optics Aftermarket

 

13,872

 

17.2

%

11,510

 

16.6

%

Total Product and Service Revenue

 

$

80,705

 

100

%

$

69,373

 

100

%

 

Cost of Revenue

 

The following table presents cost of product and service revenue and gross profit margins on product and service revenue by reportable segment for the nine months ended September 30, 2007 and 2006 (dollars in thousands):

 

 

 

2007

 

2006

 

 

 

Cost of

 

Gross Profit

 

Cost of

 

Gross Profit

 

 

 

Revenue

 

Margin

 

Revenue

 

Margin

 

Bruker AXS

 

$

90,818

 

45.0

%

$

72,100

 

41.8

%

Bruker Daltonics

 

73,167

 

41.8

%

65,795

 

41.5

%

Bruker Optics

 

40,086

 

50.2

%

33,325

 

51.9

%

Eliminations (a)

 

(7,730

)

 

 

(7,173

)

 

 

Total Cost of Revenue

 

$

196,341

 

46.0

%

$

164,047

 

45.1

%

 


(a)   represents the cost of revenues between segments which is eliminated in consolidation.

 

Bruker AXS’ cost of product and service revenue for the nine months ended September 30, 2007 was $90.8 million, resulting in a gross profit margin of 45.0%, compared to cost of product and service revenue of $72.1 million, or a gross profit margin of 41.8%, for the comparable period in 2006. The increase in gross profit margin is primarily attributable to better capacity utilization as a result of increased revenues year-over-year, the higher margin businesses acquired in the second half of 2006 and the realization of benefits from various ongoing gross profit margin improvement programs, partially offset by lower gross profit margins realized on other system revenues.

 

21



 

Bruker Daltonics’ cost of product and service revenue for the nine months ended September 30, 2007 was $73.2 million, resulting in a gross profit margin of 41.8%, compared to cost of product and service revenue of $65.8 million, or a gross profit margin of 41.5%, for the comparable period in 2006. The increase in gross profit margin is primarily attributable to increased sales of our CBRN detection systems, and a decrease in OEM life science system sales, which typically have lower margins than direct life science system sales.

 

Bruker Optics’ cost of product and service revenue for the nine months ended September 30, 2007 was $40.1 million, resulting in a gross profit margin of 50.2%, compared to cost of product and service revenue of $33.3 million, or a gross profit margin of 51.9%, for the comparable period in 2006. The decrease in gross profit margin is primarily attributable to reduced revenues from our order with the Chinese State Food and Drug Administration and a change in product mix year-over-year within the molecular spectroscopy systems, specifically lower sales of FT-NIR systems year-over-year.

 

Sales and Marketing

 

The following table presents sales and marketing expense and sales and marketing expense as a percentage of product and service revenue by reportable segment for the nine months ended September 30, 2007 and 2006 (dollars in thousands):

 

 

 

2007

 

2006

 

 

 

 

 

Percentage of

 

 

 

Percentage of

 

 

 

Sales and

 

Segment Product

 

Sales and

 

Segment Product

 

 

 

Marketing

 

and Service Revenue

 

Marketing

 

and Service Revenue

 

Bruker AXS

 

$

33,173

 

20.1

%

$

24,448

 

19.7

%

Bruker Daltonics

 

22,743

 

18.1

%

18,702

 

16.6

%

Bruker Optics

 

18,993

 

23.5

%

15,645

 

22.6

%

Total Sales and Marketing

 

$

74,909

 

20.6

%

$

58,795

 

19.7

%

 

Bruker AXS’ sales and marketing expense for the nine months ended September 30, 2007 increased to $33.2 million, or 20.1% of product and service revenue, from $24.4 million, or 19.7% of product and service revenue for the comparable period in 2006. The increase in sales and marketing expense is primarily attributable to increased headcount related to the acquisitions completed during the second half of 2006 and higher commissions on increased revenues and new order bookings year-over-year.

 

Bruker Daltonics’ sales and marketing expense for the nine months ended September 30, 2007 increased to $22.7 million, or 18.1% of product and service revenue, from $18.7 million, or 16.6% of product and service revenue for the comparable period in 2006. The increase in sales and marketing expense is attributable to incremental investments in various sales and marketing initiatives, primarily related to an increase in product specialists, direct sales, inside sales and applications resources.

 

Bruker Optics’ sales and marketing expense for the nine months ended September 30, 2007 increased to $19.0 million, or 23.5% of product and service revenue, from $15.6 million, or 22.6% of product and service revenue for the comparable period in 2006. The increase in sales and marketing expense is primarily attributable to higher commissions on increased revenues and new order bookings year-over-year, particularly in our Asia- Pacific operations.

 

General and Administrative

 

The following table presents general and administrative expense and general and administrative expense as a percentage of product and service revenue by reportable segment for the nine months ended September 30, 2007 and 2006 (dollars in thousands):

 

 

 

2007

 

2006

 

 

 

 

 

Percentage of

 

 

 

Percentage of

 

 

 

General and

 

Segment Product

 

General and

 

Segment Product

 

 

 

Administrative

 

and Service Revenue

 

Administrative

 

and Service Revenue

 

Bruker AXS

 

$

10,690

 

6.5

%

$

9,514

 

7.7

%

Bruker Daltonics

 

6,615

 

5.3

%

5,588

 

5.0

%

Bruker Optics

 

4,249

 

5.3

%

3,036

 

4.4

%

Corporate

 

2,482

 

 

 

2,181

 

 

 

Total General and Administrative

 

$

24,036

 

6.6

%

$

20,319

 

6.8

%

 

22



 

Bruker AXS’ general and administrative expenses for the nine months ended September 30, 2007 increased to $10.7 million, or 6.5% of product and service revenue, from $9.5 million, or 7.7% of product and service revenue for the comparable period in 2006. The increase in general and administrative expenses is primarily due to intangible asset amortization associated with the acquisitions completed during the second half of 2006, increased headcount and to external tax consulting fees incurred in the second quarter of 2007.

 

Bruker Daltonics’ general and administrative expense for the nine months ended September 30, 2007 increased to $6.6 million, or 5.3% of product and service revenue, from $5.6 million, or 5.0% of product and service revenue for the comparable period of 2006. The increase in general and administrative expenses is primarily attributable to external tax consulting fees incurred in the second quarter of 2007 and lower general and administrative expenses in 2006 which resulted from the collection of accounts receivable balances which previously had been written-off.

 

Bruker Optics’ general and administrative expenses for the nine months ended September 30, 2007 increased to $4.2 million, or 5.3% of product and service revenue, from $3.0 million, or 4.4% of product and service revenue for the comparable period of 2006. The increase in general and administrative expenses is primarily attributable to the allocated corporate general and administrative expenses associated with being part of a public company and external tax consulting fees incurred in the second quarter of 2007.

 

Corporate general and administrative expense for the nine months ended September 30, 2007 increased to $2.5 million from $2.2 million for the comparable period of 2006. The increase is primarily attributable to increased business development activities. Corporate general and administrative expense represents expenses associated with being a public company not allocated to our reportable segments, including legal fees, audit and consulting fees, salaries and filing fees.

 

Research and Development

 

The following table presents research and development expense and research and development expense as a percentage of product and service revenue by reportable segment for the nine months ended September 30, 2007 and 2006 (dollars in thousands):

 

 

 

2007

 

2006

 

 

 

 

 

Percentage of

 

 

 

Percentage of

 

 

 

Research and

 

Segment Product

 

Research and

 

Segment Product

 

 

 

Development

 

and Service Revenue

 

Development

 

and Service Revenue

 

Bruker AXS

 

$

16,371

 

9.9

%

$

12,727

 

10.3

%

Bruker Daltonics

 

19,920

 

15.8

%

18,287

 

16.3

%

Bruker Optics

 

6,011

 

7.4

%

5,481

 

7.9

%

Total Research and Development

 

$

42,302

 

11.6

%

$

36,495

 

12.2

%

 

Bruker AXS’ research and development expense for the nine months ended June 30, 2007 increased to $16.4 million, or 9.9% of product and service revenue, from $12.7 million, or 10.3% of product and service revenue for the comparable period in 2006. The increase in research and development expense is primarily attributable to an increase in headcount resulting from the acquisitions completed during the second half of 2006 and increased materials purchases.

 

Bruker Daltonics’ research and development expense for the nine months ended September 30, 2007 increased to $19.9 million, or 15.8% of product and service revenue, from $18.3 million, or 16.3% of product and service revenue for the comparable period in 2006. The increase in research and development expense is primarily attributable to changes in foreign currencies year-over-year, primarily the Euro, as a majority of research and development is performed in Germany and increased materials purchases.

 

Bruker Optics’ research and development expense for the nine months ended September 30, 2007 increased to $6.0 million, or 7.4% of product and service revenue, from $5.5 million, or 7.9% of product and service revenue for the comparable period in 2006. The increase in research and development expense is primarily attributable to changes in foreign currencies year-over-year, primarily the Euro, as a majority of research and development is performed in Germany.

 

23



 

Acquisition Related Charges

 

On April 18, 2006, we announced that we had entered into a definitive agreement to acquire all of the stock of molecular spectroscopy company Bruker Optics. The acquisition of Bruker Optics was approved by our shareholders on June 29, 2006 and was subsequently completed on July 1, 2006. This acquisition represented a business combination of companies under common control due to a majority ownership by individuals of both Bruker BioSciences and Bruker Optics and, as a result, transaction costs have been expensed as incurred rather than being included in a purchase price allocation. During the nine months ended September 30, 2006, we incurred acquisition related charges totaling $5.8 million, which consisted of investment banking, legal and accounting fees, compensation earned by the special committee of our Board of Directors and antitrust regulation filing fees.

 

Interest and Other Income (Expense), Net

 

Interest and other income (expense), net, during the nine months ended September 30, 2007 was $(0.8) million, compared to $3.5 million during the nine months ended September 30, 2006. During the nine months ended September 30, 2007, the major components within interest and other income (expense), net, were net interest expense of $(0.4) million, losses on foreign currency transactions of $(1.7) million and the appreciation of the fair value of derivative financial instruments of $0.8 million. During the nine months ended September 30, 2006, the major components within interest and other income (expense), net, were net interest income of $0.4 million, losses on foreign currency transactions of $(1.2) million and the appreciation of the fair value of derivative financial instruments of $3.9 million.

 

Provision for Income Taxes

 

The income tax provision for the nine months ended September 30, 2007 was $7.7 million compared to an income tax provision of $9.4 million for the nine months ended September 30, 2006, representing effective tax rates of 30.1% and 51.5%, respectively. The lower effective tax rate in the first nine months of 2007 compared to the first nine months of 2006 was primarily due to new legislation in Germany. The Company has analyzed the impact of these changes on its deferred tax assets and liabilities as of the date of enactment. The temporary differences that will reverse after December 31, 2007 have been adjusted to reflect the new tax rate which will become effective on January 1, 2008. As a result, the Company has recorded a net reduction to income tax expense of $2.4 million in the quarter ending September 30, 2007. Our effective tax rate is calculated using our projected annual pre-tax income or loss and is affected by research and development tax credits, the expected level of other tax benefits, and the impact of changes to the valuation allowance, as well as changes in the mix of our pre-tax income and losses among jurisdictions with varying statutory tax rates and credits.

 

Minority Interest in Consolidated Subsidiaries

 

Minority interest in consolidated subsidiaries for the nine months ended September 30, 2007 was $0.3 million compared to $0.1 million in the comparable period of 2006. The minority interest in subsidiaries represents the minority shareholders’ proportionate share of net income of those subsidiaries for the nine months ended September 30, 2007 and 2006. For the nine months ended September 30, 2007 and 2006, the minority interest relates to our two majority-owned subsidiaries, Incoatec GmbH and Bruker Baltic Ltd.

 

LIQUIDITY AND CAPITAL RESOURCES

 

We currently anticipate that our existing cash will be sufficient to support our operating and investing needs for at least the next twelve months, but this depends on our profitability and our ability to manage working capital requirements. Future cash requirements could also be affected by potential acquisitions that we may consider. Historically, we have financed our growth through a combination of debt financings and issuances of common stock. Most recently, on February 12, 2007, we and a group of selling stockholders completed a public offering which generated net proceeds of approximately $16.9 million to us. In the future, there can be no assurance that additional financing alternatives will be available to us if required, or if available, will be obtained with terms favorable to us.

 

During the nine months ended September 30, 2007, net cash used by operating activities was $10.2 million, compared to net cash provided by operating activities of $17.8 million during the nine months ended September 30, 2006. The change in cash from operating activities was primarily attributable to an increase in inventory balances and a decrease in customer deposits, partially offset by improved operating results year-over-year and increases in accounts payable, deferred revenue and income taxes payable.

 

During the nine months ended September 30, 2007, investing activities used $16.5 million in cash compared to net cash provided by investing activities of $13.7 million during the nine months ended September 30, 2006. Cash used by investing activities during the nine months ended September 30, 2007 was attributable primarily to $13.3 million in capital expenditures and $2.9 million used for acquisitions, net of cash acquired. Cash provided by investing activities during the nine months ended September 30, 2006 was attributable primarily to approximately $46.5 million from the redemption of short-term investments offset by $27.6 million used for acquisitions, net of cash acquired, and $5.0 million in capital expenditures.

 

In connection with our acquisition of Roentec AG, additional consideration, in the amount of approximately $2.0 million,

 

24



 

may be paid to Roentec’s former management, employee and consultant shareholders based on the 2006 and 2007 revenue performance of Roentec. If these payments are required, they will be comprised of either, at our option, 50% our restricted common stock and 50% cash, or 100% cash. For 2006, approximately $1.3 million in cash was paid in March 2007 to Roentec’s former shareholders.

 

In January 2006, we acquired Socabim SAS, a privately-held company focused on advanced X-ray analysis software for materials research based in Paris, France. The initial aggregate purchase price of approximately $8.8 million was paid through the issuance of 267,302 restricted shares of our common stock to Socabim’s two largest shareholders, which had an aggregate value of approximately $1.3 million as of the date of issuance, and an aggregate of $7.5 million was paid to all of the Socabim selling shareholders from cash on hand. Additional cash consideration, in the amount of approximately $1.5 million in total, may be paid through 2009 based on the future performance of Socabim. For 2006, approximately $356,000 in cash was paid in 2007 to Socabim’s former shareholders.

 

In September 2006, we acquired all of the capital stock of Quantron GmbH, a spark-OES company based in Kleve, Germany.  In accordance with the stock purchase agreement, at the closing, we paid an aggregate of approximately $6.3 million of consideration to the sellers, of which approximately $5.0 million was paid in cash and approximately $1.3 million was paid through the issuance of an aggregate of 202,223 restricted unregistered shares of our common stock, par value $0.01 per share, to Quantron’s two largest shareholders. Pursuant to the earn-out provisions of the stock purchase agreement, up to an aggregate of $4.7 million of additional cash consideration may be paid through 2009 based on the future performance of Quantron. At September 30, 2007, no additional cash consideration has been paid.

 

In January 2007, we acquired all of the assets of Keca Metal Products, Ltd. (“Keca”), a Texas partnership located in Spring, Texas. The aggregate purchase price for Keca was $0.6 million and was funded with cash on hand.

 

In June 2007, we acquired all of the capital stock of Analys-Konsult AB (“AKAB”), a distributor and service provider of scientific instrumentation based in Sweden. The aggregate purchase price of AKAB was approximately $0.8 million, of which approximately $0.5 million was paid in cash and approximately $0.3 million was paid through the issuance of an aggregate of 29,740 restricted unregistered shares of our common stock to AKAB’s shareholders.

 

During the nine months ended September 30, 2007, financing activities provided $10.9 million of cash compared to net cash used by financing activities of $53.2 million during the nine months ended September 30, 2006. The change in cash from financing activities in the first nine months of 2007 was due to approximately $18.9 million in net proceeds from the public offering of common stock along with subsequent stock option exercises, partially offset by $6.5 million in net repayments of short-term borrowings. Cash used by financing activities during the nine months ended September 30, 2006 was attributable primarily to approximately $74.0 million paid to shareholders in connection with the Bruker Optics acquisition, partially offset by $19.5 million in net proceeds from short-term borrowings.

 

At September 30, 2007, we had a demand line of credit with Citizens Bank in the United States with a maximum available amount of $75.0 million. The line of credit is secured by a pledge to the bank of 100% of the capital stock of each of the Company’s wholly-owned domestic subsidiaries, each of which also pledged a portion of the stock of certain of their foreign subsidiaries. As of September 30, 2007, our U.S. line of credit was fully available. We also maintain revolving lines of credit totaling approximately $44.4 million with various German, Japanese and Swedish banks. The German, Japanese and Swedish lines of credits are unsecured and as of September 30, 2007 approximately $13.8 million, in the aggregate, was outstanding on these lines of credit.

 

In addition to our lines of credit, we have both short-term and long-term notes payable with outstanding balances aggregating $25.3 million as of September 30, 2007. The interest rates on these obligations range from 1.8% to 8.01%. We entered into an interest rate swap to hedge the variability of cash flows related to changes in interest rates on borrowings of variable debt obligations and pay a 4.6% fixed rate of interest and receive a variable rate of interest based on the Securities Industry and Financial Markets Association SWAP Index. The interest rate swap has a notional value of $1.7 million which decreases in conjunction with the State of Wisconsin industrial revenue bonds (IRB) payment schedule until the interest rate swap and IRB agreements terminate in December 2013.

 

The following table summarizes maturities for our significant financial obligations as of September 30, 2007 (in thousands):

 

 

 

 

 

Less than

 

1-3

 

4-5

 

More than

 

Contractual Obligations

 

Total

 

1 year

 

years

 

years

 

5 years

 

Short-term borrowings

 

$

21,014

 

$

21,014

 

$

 

$

 

$

 

Long-term borrowings

 

18,078

 

 

14,986

 

2,150

 

942

 

Pension

 

13,157

 

152

 

687

 

1,273

 

11,045

 

Total contractual obligations

 

$

52,249

 

$

21,166

 

$

15,673

 

$

3,423

 

$

11,987

 

 

In connection with some of our outstanding debt, we are required to maintain certain financial ratios and meet other

 

25



 

financial criteria. Additionally, we are subject to a variety of restrictive covenants that require bank consent if not met. As of September 30, 2007, the latest measurement date, we were in compliance with all financial covenants.

 

As of September 30, 2007, we have approximately $12.3 million of net operating loss carryforwards available to reduce future U.S. taxable income. These losses have various expiration dates through 2026. We also had foreign tax credits of approximately $5.0 million that expire in 2016 and research and development tax credits of approximately $3.1 million available to offset future U.S. tax liabilities that expire at various dates through 2025.

 

Recent Accounting Pronouncements

 

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Liabilities, Including an amendment of FASB Statement No. 115 (“SFAS 159”). This Statement permits entities to choose to measure many financial instruments and certain other items at fair value that are not currently required to be measured at fair value. SFAS 159 is effective as of the beginning of fiscal 2008. The Company has not yet assessed the effect, if any, that adoption of SFAS 159 will have on its results of operations and financial position.

 

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (“SFAS 157”). This Statement is effective for financial statements issued for fiscal years beginning after November 15, 2007. SFAS 157 provides a common fair value hierarchy for companies to follow in determining fair value measurements in the preparation of financial statements and expands disclosure requirements relating to how such fair value measurements were developed. SFAS 157 clarifies the principle that fair value should be based on the assumptions that the marketplace would use when pricing an asset or liability, rather than company specific data. The Company is currently assessing the impact that SFAS 157 will have on its results of operations and financial position.

 

ITEM 3:  Quantitative and Qualitative Disclosures About Market Risk

 

We are potentially exposed to market risk associated with changes in foreign exchange and interest rates for which we selectively use financial instruments to reduce related market risks. An instrument is treated as a hedge if it is effective in offsetting the impact of volatility in our underlying exposure. We have also entered into instruments which are not effective derivatives under the requirements of SFAS No. 133, and therefore such instruments are not designated as hedges. All transactions are authorized and executed pursuant to our policies and procedures. Analytical techniques used to manage and monitor foreign exchange and interest rate risk include market valuations and sensitivity analysis.

 

The Company regularly invests excess cash in overnight repurchase agreements and interest-bearing investment-grade securities that we hold for the duration of the term of the respective instrument and are subject to changes in short-term interest rates. The Company believes that the market risk arising from holding these financial instruments is minimal.

 

The Company’s exposure to market risks associated with changes in interest rates relates primarily to the increase or decrease in the amount of interest income earned on its investment portfolio. The Company ensures the safety and preservation of invested funds by limiting default risk, market risk and reinvestment risk. The Company mitigates default risk by investing in investment grade securities. Declines in interest rates over time will, however, reduce the Company’s interest income.

 

Impact of Foreign Currencies

 

We sell products in many countries, and a substantial portion of sales and expenses are denominated in foreign currencies, principally in the Euro and Japanese Yen. Fluctuations in the rate of exchange between the U.S. dollar and foreign currencies could adversely affect our financial results. Costs related to these sales are largely denominated in the same respective currencies, thereby limiting our transaction risk exposure. However, for sales not denominated in U.S. dollars, if there is an increase in the rate at which a foreign currency is exchanged for U.S. dollars, it will require more of the foreign currency to equal a specified amount of U.S. dollars than before the rate increase. In such cases, if we price our products in the foreign currency, we will receive less in U.S. dollars than we did before the rate increase went into effect. If we price our products in U.S. dollars and competitors price their products in local currency, an increase in the relative strength of the U.S. dollar could result in our prices not being competitive in a market where business is transacted in the local currency.

 

We have entered into forward currency exchange contracts having maturities of less than twelve months with notional amounts aggregating $2.3 million. These contracts involve the purchase of Japanese Yen, Singapore Dollars, U.S. Dollars and EURO currency at fixed U.S. dollar and EURO amounts. The notional amounts of the contracts are intended to hedge receivables in U.S. dollars and EURO. These transactions do not qualify for hedge accounting under SFAS No. 133. Accordingly, the instruments are marked-to-market with the corresponding gains and losses recorded in other income (expense) in the current period.

 

At the end of each reporting period, we obtain third-party verification as to the fair value of these instruments.  As of September 30, 2007 and 2006, the currency exchange contracts had a favorable fair value of $0.0 million and a favorable fair value of $0.7 million, respectively. The instruments’ fair market values are recorded net of each other on the balance sheet. In connection with these instruments, we recorded a net gain of $0.2 million and $0.1 million during the three months ended

 

26



 

September 30, 2007 and 2006, respectively, and a net gain of $0.4 million and $3.9 million during the nine months ended September 30, 2007 and 2006, respectively.

 

Realized foreign exchange losses were approximately $(1.1) million and $(0.1) million for the three months ended September 30, 2007 and 2006, respectively, and approximately $(1.7) million and $(1.2) million for the nine months ended September 30, 2007 and 2006, respectively. As we continue to expand internationally, we evaluate currency risks and may enter into foreign exchange contracts on a more consistent basis or from time to time as circumstances require to mitigate foreign currency exposure.

 

We have entered into foreign-denominated debt obligations. The currency effects of the debt obligations are reflected in interest and other income (expense), net, on the consolidated statement of operations. We also have foreign-denominated intercompany borrowing arrangements with our Bruker Daltonik GmbH subsidiary in Germany that affected accumulated other comprehensive income (loss). A 10% increase or decrease of the respective foreign exchange rate with our Bruker Daltonik GmbH subsidiary in Germany would result in a change in accumulated other comprehensive income (loss) of approximately $3.1 million or $(2.5) million, respectively.

 

Impact of Interest Rates

 

Our exposure related to adverse movements in interest rates is derived primarily from outstanding floating rate debt instruments that are indexed to short-term market rates and cash equivalents. Our objective in managing our exposure to interest rates is to decrease the volatility that changes in interest rates might have on our earnings and cash flows. To achieve this objective, we use a fixed rate agreement to adjust a portion of our debt that is subject to variable interest rates.

 

In the United States, we have entered into an interest rate swap arrangement to limit the interest rate exposure on our $2.0 million industrial revenue bond to a fixed rate of 4.6%. We pay a 4.6% fixed rate of interest and receive a variable rate of interest based on the Securities Industry and Financial Markets Association SWAP Index on a $1.7 million notional amount. Net interest payments or receipts are recorded as adjustments to interest expense. In addition, the instrument is recorded at fair market value on our balance sheet, and changes in the fair market value are recorded in current earnings since the arrangement is not considered an effective hedge. As of September 30, 2007, the fair value of the instrument was approximately $(0.1) million, net of tax, and is recorded as a liability on the balance sheet.

 

In 2002, we entered into two derivative financial instruments: a cross currency interest rate swap and an interest rate swap. The cross currency interest rate swap is for 5.0 million Euro and we receive semiannual interest payments in Euro based on a variable interest rate equal to the six-month EURIBOR rate in exchange for semiannual payments in Swiss francs at a fixed rate of 4.97%. The interest rate swap of 3.0 million Euro reduced the 6-month EURIBOR rate by 1.80% per annum until January 4, 2007. We entered into the financial instruments to manage our exposure to interest rates and foreign exchange risk. Until the instruments become an effective hedge, the instruments are considered speculative and are marked-to-market through interest and other income (expense), net, on the consolidated statement of operations. As of September 30, 2007 and 2006, the cross currency interest rate swap had an unfavorable fair value of $(0.6) million and $(0.0) million, respectively. As of September 30, 2006, the interest rate swap had an unfavorable fair value of approximately $(29,000).

 

A 10% increase or decrease in the average cost of our variable rate debt would not result in a material change in pre-tax interest expense.

 

Inflation

 

We do not believe inflation had a material impact on our business or operating results during any of the periods presented.

 

ITEM 4:  Controls and Procedures

 

Our Company’s management, with the participation of the Chief Executive Officer and Chief Financial Officer, has conducted an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2007. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls were effective at September 30, 2007.

 

We maintain internal controls and procedures designed to ensure that we are able to collect the information subject to required disclosure in reports we file with the United States Securities and Exchange Commission, and to process, summarize and disclose this information within the time specified by the rules set forth by the Securities and Exchange Commission.

 

There were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2007 that materially affected, or are reasonably likely to affect, our internal control over financial reporting.

 

27



 

PART II  OTHER INFORMATION

 

ITEM 1:  Legal Proceedings

 

General

 

The Company may, from time to time, be involved in legal proceedings in the ordinary course of business. The Company is not currently involved in any pending legal proceedings that, either individually or taken as a whole, are reasonably likely in management’s judgment to materially harm our business, prospects, results of operations or financial condition, nor have any such legal proceedings been threatened.

 

ITEM 1A:  Risk Factors

 

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2006, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

 

There have been no material changes to the risk factors disclosed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2006.

 

ITEM 2:  Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

ITEM 3:  Defaults Upon Senior Securities

 

None.

 

ITEM 4:  Submission of Matters to a Vote of Security Holders

 

None.

 

ITEM 5:  Other Information

 

None.

 

ITEM 6:  Exhibits

 

31.1

 

Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (1).

31.2

 

Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (1).

32.1

 

Certification by Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (2).

 


 

(1)

Filed herewith

 

(2)

Furnished herewith

 

28



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

BRUKER BIOSCIENCES CORPORATION

 

 

 

 Date: November 6, 2007

 

By:

/s/ Frank H. Laukien, Ph.D.

 

 

 

Frank H. Laukien, Ph.D.

President, Chairman, Chief Executive Officer, and Director

(Principal Executive Officer)

 

 

 

 

 

 

 

 

 Date: November 6, 2007

 

By:

/s/ William J. Knight

 

 

 

William J. Knight

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

29